Dr. Carome:

Thank you for your recent letter. In response, we have corrected the conflict of interest disclosure for Dr. Musiek as below to reflect for our readers the relationship between Eisai and Biogen regarding aducanamab. Dr. Musiek's relationship with Eisai has not involved aducanamab.

Sincerely,

Andy Josephson
Editor, JAMA Neurology

The correction has been published and the disclosure statement now reads:

“Conflict of Interest Disclosures: Dr Musiek reports grants from Eisai Pharmaceuticals, the National Institutes of Health, and Cure Alzheimer’s Fund outside of this work and consulting for Eisai Pharmaceuticals, which (along with Biogen) is involved in developing and commercializing aducanumab for treatment of Alzheimer disease.”

https://jamanetwork.com/journals/jamaneurology/fullarticle/2773648